Organogenesis Provides Update on Second Phase 3 ReNu® Study

Published

Company maintains confidence in ReNu as innovative pain management therapy

  • Second Phase 3 trial demonstrates numerical improvement in baseline pain reduction over the first Phase 3 trial despite not meeting the primary endpoint
  • Statistically significant maintenance of function (p

    The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ORGO